gemfibrozil has been researched along with angiotensin ii in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Li, QZ; Nie, S; Ye, HJ; Zhao, SP; Zhou, HN | 1 |
| Guzik, TJ; Harrison, DG | 1 |
3 other study(ies) available for gemfibrozil and angiotensin ii
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease.
Topics: Aged; Angiotensin II; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; Cells, Cultured; Coronary Disease; Gemfibrozil; Humans; Kidney Function Tests; Leukocytes, Mononuclear; Lipids; Liver Function Tests; Middle Aged; Tumor Necrosis Factor-alpha | 2003 |
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil; Humans; Hypertension; I-kappa B Proteins; Inflammation; Kidney Diseases; Mice; Models, Cardiovascular; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type III; Organ Specificity; Sodium Chloride, Dietary | 2007 |